Yacine Tandjaoui-Lambiotte
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Wind | 1 | 2021 | 144 | 0.85 | Why? |
| Interferon Type I | 4 | 2021 | 2789 | 0.34 | Why? |
| Autoantibodies | 3 | 2021 | 2094 | 0.29 | Why? |
| Air Pollutants | 1 | 2021 | 3110 | 0.26 | Why? |
| Catastrophic Illness | 1 | 2019 | 41 | 0.20 | Why? |
| Genetic Diseases, X-Linked | 1 | 2021 | 237 | 0.18 | Why? |
| Ubiquitin-Protein Ligases | 1 | 2021 | 249 | 0.18 | Why? |
| Loss of Function Mutation | 1 | 2020 | 244 | 0.18 | Why? |
| Toll-Like Receptor 7 | 1 | 2021 | 402 | 0.17 | Why? |
| Immune System Diseases | 1 | 2021 | 410 | 0.16 | Why? |
| Antibodies, Antiphospholipid | 1 | 2019 | 519 | 0.14 | Why? |
| Plasma Exchange | 1 | 2021 | 763 | 0.13 | Why? |
| Antiphospholipid Syndrome | 1 | 2019 | 533 | 0.12 | Why? |
| Social Class | 1 | 2020 | 1360 | 0.12 | Why? |
| Continuous Positive Airway Pressure | 1 | 2021 | 1187 | 0.11 | Why? |
| Environmental Monitoring | 1 | 2021 | 3143 | 0.09 | Why? |
| Noninvasive Ventilation | 1 | 2021 | 2329 | 0.09 | Why? |
| Asymptomatic Infections | 3 | 2020 | 7218 | 0.08 | Why? |
| Alleles | 2 | 2021 | 1557 | 0.07 | Why? |
| Nedd4 Ubiquitin Protein Ligases | 1 | 2021 | 43 | 0.06 | Why? |
| Penetrance | 1 | 2021 | 121 | 0.06 | Why? |
| Endosomal Sorting Complexes Required for Transport | 1 | 2021 | 67 | 0.06 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.06 | Why? |
| Interferon Regulatory Factor-7 | 1 | 2020 | 234 | 0.05 | Why? |
| Pedigree | 1 | 2021 | 502 | 0.05 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.05 | Why? |
| Ubiquitination | 1 | 2021 | 343 | 0.05 | Why? |
| Genetic Loci | 1 | 2020 | 439 | 0.05 | Why? |
| Receptor, Interferon alpha-beta | 1 | 2020 | 610 | 0.04 | Why? |
| Toll-Like Receptor 3 | 1 | 2020 | 391 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2021 | 9044 | 0.04 | Why? |
| Benchmarking | 1 | 2021 | 627 | 0.04 | Why? |
| Paris | 1 | 2020 | 1287 | 0.04 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.04 | Why? |
| Air Filters | 1 | 2021 | 443 | 0.04 | Why? |
| Aged | 8 | 2021 | 215776 | 0.03 | Why? |
| Infant | 3 | 2021 | 30274 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2021 | 1755 | 0.03 | Why? |
| Interferon-alpha | 1 | 2021 | 1442 | 0.03 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2021 | 1439 | 0.03 | Why? |
| Adult | 8 | 2021 | 244371 | 0.03 | Why? |
| Diagnostic Errors | 1 | 2019 | 865 | 0.03 | Why? |
| Child, Preschool | 3 | 2021 | 36283 | 0.03 | Why? |
| Indoles | 1 | 2021 | 1243 | 0.03 | Why? |
| Middle Aged | 8 | 2021 | 270681 | 0.03 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.03 | Why? |
| Humans | 12 | 2021 | 930598 | 0.03 | Why? |
| Critical Pathways | 1 | 2021 | 1587 | 0.03 | Why? |
| Mice, Inbred BALB C | 1 | 2021 | 5814 | 0.03 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Ventilators, Mechanical | 1 | 2021 | 2193 | 0.02 | Why? |
| Male | 7 | 2021 | 367725 | 0.02 | Why? |
| Child | 3 | 2021 | 70012 | 0.02 | Why? |
| Female | 7 | 2021 | 380317 | 0.02 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.02 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.02 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2020 | 4027 | 0.02 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.02 | Why? |
| Survival Analysis | 1 | 2019 | 7592 | 0.02 | Why? |
| Vero Cells | 1 | 2021 | 14117 | 0.02 | Why? |
| Research Design | 1 | 2021 | 5830 | 0.02 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.02 | Why? |
| France | 1 | 2019 | 12074 | 0.02 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Mice | 1 | 2021 | 21357 | 0.01 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2021 | 10083 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.01 | Why? |
| Prevalence | 1 | 2019 | 25773 | 0.01 | Why? |
| Thrombosis | 1 | 2019 | 7504 | 0.01 | Why? |
| Prognosis | 1 | 2019 | 32490 | 0.01 | Why? |
| Treatment Outcome | 1 | 2021 | 51732 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Animals | 1 | 2021 | 78931 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |
| Retrospective Studies | 1 | 2019 | 105322 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.00 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.00 | Why? |